Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inovio Pharmaceuticals : Reports Narrower Q2 Loss on Higher Revenue

08/09/2021 | 04:29pm EDT


ę MT Newswires 2021
All news about INOVIO PHARMACEUTICALS, INC.
10/12INOVIO PHARMACEUTICALS : Announces Online Preprint Publication of Homologous Boosting Data..
PR
10/12Inovio Pharmaceuticals, Inc. Announces Online Preprint Publication of Homologous Boosti..
CI
10/11INOVIO PHARMACEUTICALS : Secures Approval to Conduct Phase 3 Trial of COVID-19 DNA Vaccine..
MT
10/11INOVIO PHARMACEUTICALS : Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate ..
PR
10/11INOVIO Expands Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include..
CI
09/29INOVIO PHARMACEUTICALS : to Present Three Posters at IDWeek 2021
PR
09/22INOVIO PHARMACEUTICALS : Gets Approval from Mexico Regulator for COVID-19 Vaccine Efficacy..
MT
09/22INOVIO PHARMACEUTICALS : Receives Regulatory Authorization to Conduct Phase 3 Efficacy Tri..
PR
09/22INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID..
CI
09/10INOVIO PHARMACEUTICALS : BofA Securities Downgrades Inovio Pharmaceuticals to Underperform..
MT
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 4,71 M - -
Net income 2021 -272 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,40x
Yield 2021 -
Capitalization 1 477 M 1 477 M -
Capi. / Sales 2021 314x
Capi. / Sales 2022 15,0x
Nbr of Employees 262
Free-Float 98,3%
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 7,02 $
Average target price 13,22 $
Spread / Average Target 88,4%
EPS Revisions
Managers and Directors
J. Joseph Kim President, Chief Executive Officer & Director
Peter D. Kies Chief Financial Officer
Simon X. Benito Chairman
Laurent M. Humeau Chief Scientific Officer
Kate E. Broderick Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
INOVIO PHARMACEUTICALS, INC.-20.68%1 477
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414